Asthma and COVID-19: What do we know now

Hughes-Visentin, Alexzandra; Paul, Anthea B. Mahesan

doi:10.1177/1179548420966242

Cited by 28 publications

(49 citation statements)

References 63 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on clinical and population-based studies, non-Hispanic Black and Latino individuals and communities are at increased risk for COVID-19 exposure [ 17 , 19 , 20 , 22 ], morbidity [ 8 , 9 , 23 , 24 ], and mortality [ 7 , 25 , 26 ]. Numerous chronic health conditions, including hypertension [ 8 , 23 , 26 - 29 ], diabetes [ 11 , 23 , 27 , 28 , 30 ], cancer [ 15 , 31 - 33 ], chronic obstructive pulmonary disease (COPD) [ 34 - 36 ] and asthma [ 28 , 37 - 39 ], and obesity [ 40 - 43 ] have been associated with an increased risk for poor COVID-19 outcomes.…”

Section: Introductionmentioning

confidence: 99%

Attitudes Toward Using COVID-19 mHealth Tools Among Adults With Chronic Health Conditions: Secondary Data Analysis of the COVID-19 Impact Survey

Camacho-Rivera¹,

Islam²,

Rivera³

et al. 2020

JMIR Mhealth Uhealth

View full text Add to dashboard Cite

Background Adults with chronic conditions are disproportionately burdened by COVID-19 morbidity and mortality. Although COVID-19 mobile health (mHealth) apps have emerged, research on attitudes toward using COVID-19 mHealth tools among those with chronic conditions is scarce. Objective This study aimed to examine attitudes toward COVID-19, identify determinants of COVID-19 mHealth tool use across demographic and health-related characteristics, and evaluate associations between chronic health conditions and attitudes toward using COVID-19 mHealth tools (eg, mHealth or web-based methods for tracking COVID-19 exposures, symptoms, and recommendations). Methods We used nationally representative data from the COVID-19 Impact Survey collected from April to June 2020 (n=10,760). Primary exposure was a history of chronic conditions, which were defined as self-reported diagnoses of cardiometabolic, respiratory, immune-related, and mental health conditions and overweight/obesity. Primary outcomes were attitudes toward COVID-19 mHealth tools, including the likelihood of using (1) a mobile phone app to track COVID-19 symptoms and receive recommendations; (2) a website to track COVID-19 symptoms, track location, and receive recommendations; and (3) an app using location data to track potential COVID-19 exposure. Outcome response options for COVID-19 mHealth tool use were extremely/very likely, moderately likely, or not too likely/not likely at all. Multinomial logistic regression was used to compare the likelihood of COVID-19 mHealth tool use between people with different chronic health conditions, with not too likely/not likely at all responses used as the reference category for each outcome. We evaluated the determinants of each COVID-19 mHealth intervention using Poisson regression. Results Of the 10,760 respondents, 21.8% of respondents were extremely/very likely to use a mobile phone app or a website to track their COVID-19 symptoms and receive recommendations. Additionally, 24.1% of respondents were extremely/very likely to use a mobile phone app to track their location and receive push notifications about whether they have been exposed to COVID-19. After adjusting for age, race/ethnicity, sex, socioeconomic status, and residence, adults with mental health conditions were the most likely to report being extremely/very or moderately likely to use each mHealth intervention compared to those without such conditions. Adults with respiratory-related chronic diseases were extremely/very (conditional odds ratio 1.16, 95% CI 1.00-1.35) and moderately likely (conditional odds ratio 1.23, 95% CI 1.04-1.45) to use a mobile phone app to track their location and receive push notifications about whether they have been exposed to COVID-19. Conclusions Our study demonstrates that attitudes toward using COVID-19 mHealth tools vary widely across modalities (eg, web-based method vs app) and chronic health conditions. These findings may inform the adoption of long-term engagement with COVID-19 apps, which is crucial for determining their potential in reducing disparities in COVID-19 morbidity and mortality among individuals with chronic health conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Attitudes Toward Using COVID-19 mHealth Tools Among Adults With Chronic Health Conditions: Secondary Data Analysis of the COVID-19 Impact Survey

Camacho-Rivera¹,

Islam²,

Rivera³

et al. 2020

JMIR Mhealth Uhealth

View full text Add to dashboard Cite

show abstract

“…Certain aspects of the type-2 immune response, including type 2 cytokines (IL- 4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19 due to its anti-inflammatory effects 8 , 23 . For example, IL-4 can suppress type-1 immune response 8 .…”

Section: Resultsmentioning

confidence: 99%

Severe asthma in the era of COVID-19: A narrative review

et al. 2022

View full text Add to dashboard Cite

Introduction and objectives: Severe asthma management during the coronavirus disease 2019 (COVID-19) pandemic is a challenge and will continue to be, at least in the next few months, as herd immunity is still a mirage. A lot has to be learned about how COVID-19 affects underlying diseases, and severe asthma is no exception. Methods: Narrative review of papers available until February 2021 in PubMed and Google Scholar, relating severe asthma and COVID-19. Four main research topics were reviewed: SARS-CoV-2 infection: immunology and respiratory pathology; interrelationship of severe asthma endotypes and COVID-19 disease mechanisms; severe asthma epidemiology and COVID-19; and biologics for severe asthma in the context of COVID-19. Results: COVID-19 disease mechanisms start with upper respiratory cell infection, and afterwards several immunological facets are activated, contributing to disease severity, namely cell-mediated immunity and antibody production. Although infrequent in the COVID-19 course some patients develop a cytokine storm that causes organ damage and may lead to acute respiratory distress syndrome or multiorgan failure. Regarding severe asthma endotypes, type2-high might have a protective role both in infection risk and disease course. There is conflicting data regarding the epidemiological relationship between COVID-19 among severe asthma patients, with some studies reporting increased risk of infection and disease course, whereas others the other way round. Biologics for severe asthma do not seem to increase the risk of infection and severe COVID-19, although further evidence is needed. Conclusions: Globally, in the era of COVID-19, major respiratory societies recommend continuing the biologic treatment, preferably in a self-home administration program.

show abstract

“…Some protective factors against SARS-COV-2 infection have been hypothesized in patients with allergic asthma, such as T2 immune response ( Figure 1 ), overproduction of mucus, and asthma treatment ( 27 – 30 ).…”

Section: Protective Factors Against Sars-cov-2 Infection In Children With Asthmamentioning

confidence: 99%

“…Overall, these results suggest that Th2 immune responses may be a protective factor against SARS-COV-2 infection by causing ACE 2 down-regulation ( 32 ). Additionally, since eosinopenia has been observed in COVID-19 patients, the increased number of eosinophils in asthmatic patients could have a protective role against SARS-COV-2 ( 27 ). Though the relationship between eosinophil levels and COVID-19 is still not clear, during the pandemic it is important to monitor eosinophil counts and the clinical course of COVID-19 in patients with asthma treated with biological drugs responsible for decreased eosinophil levels ( 33 ).…”

Section: Protective Factors Against Sars-cov-2 Infection In Children With Asthmamentioning

confidence: 99%

An Overview of Asthma and COVID-19: Protective Factors Against SARS-COV-2 in Pediatric Patients

2021

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by severe acute respiratory syndrome coronavirus SARS-COV-2. Aberrant innate immunity response and cytokine storm are responsible for the syndrome. Apparently, in asthmatic patients, the inadequate antiviral immune response and the tendency for asthma exacerbation evoked by common respiratory viruses could explain increased susceptibility to SARS-COV-2 infection. However, asthma has not been suggested to be a risk factor in COVID-19 patients. Therefore, in asthmatic patients some potential protective mechanisms against SARS-COV-2 have been hypothesized, like type 2 immune response, number of eosinophils, overproduction of mucus, and asthma treatment, along with behavioral factors not strictly related to asthma, such as social distancing, hygiene measures and wearing facemasks, that contribute to reduce the individual susceptibility to SARS-COV-2 infection. In this mini-review, we will describe the current literature regarding potential protective factors against COVID-19 in children with asthma based on the evidence available so far.

show abstract

Asthma and COVID-19: What do we know now

Cited by 28 publications

References 63 publications

Attitudes Toward Using COVID-19 mHealth Tools Among Adults With Chronic Health Conditions: Secondary Data Analysis of the COVID-19 Impact Survey

Attitudes Toward Using COVID-19 mHealth Tools Among Adults With Chronic Health Conditions: Secondary Data Analysis of the COVID-19 Impact Survey

Severe asthma in the era of COVID-19: A narrative review

An Overview of Asthma and COVID-19: Protective Factors Against SARS-COV-2 in Pediatric Patients

Contact Info

Product

Resources

About